Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 13/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL5581355 | 0.87 | ACHE (0.44) | ALDH1A1ACHE | |
| Bromide SCHEMBL5581090 | 0.83 | ACHE (0.48) | ALDH1A1ACHE | |
| Iodide SCHEMBL5581465 | 0.81 | ALDH1A1 (0.42) | ALDH1A1ACHELMNA | |
| Iodide SCHEMBL5581390 | 0.80 | ACHE (0.48) | ALDH1A1ACHEKDM4E | |
| Iodide SCHEMBL5581467 | 0.79 | ACHE (0.50) | ALDH1A1ACHELMNA | |
| Iodide SCHEMBL5581565 | 0.77 | ALDH1A1 (0.48) | ALDH1A1ACHEAPOBEC3AAPOBEC3GLMNA | |
| Iodide SCHEMBL5581330 | 0.76 | ACHE (0.48) | ALDH1A1ACHE | |
| Iodide SCHEMBL5581993 | 0.76 | CYP2D6 (0.51) | ALDH1A1ACHE | |
| Hydrochloric Acid SCHEMBL11775312 | 0.76 | LMNA (0.54) | ALDH1A1ACHEKDM4ELMNA | |
| Bromide SCHEMBL5581061 | 0.76 | ACHE (0.53) | ALDH1A1ACHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070166296-A1 | Therapeutic Systems | ENZACTA R & D LIMITED | 2007-07-19 | — | — | US | disclosed |
| US-7138122-B2 | Therapeutic systems | ENZACTA R & D LIMITED (GB) | 2006-11-21 | — | — | US | disclosed |
| EP-0988059-B8 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | PROTHERICS MOLECULAR DESIGN LT (GB) | 2006-03-01 | — | — | EP | disclosed |
| EP-0988059-B1 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LTD (GB) | 2005-12-07 | — | — | EP | disclosed |
| US-6867231-B1 | Therapeutic systems | ENZACTA R & D LIMITED (GB) | 2005-03-15 | — | — | US | disclosed |
| EP-1468698-A2 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LIMITED (GB) | 2004-10-20 | — | — | EP | disclosed |
| US-20030086933-A1 | Therapeutic systems | ENZACTA R & D LIMITED | 2003-05-08 | — | — | US | disclosed |
| EP-0988059-A2 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LIMITED (GB) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998057662-A2 | THERAPEUTIC SYSTEMS | ENZACTA R & D LIMITED (GB) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070166296-A1 | Therapeutic Systems | NQO2, NQO1, NAPRT | ACHE 4315/4885ALDH1A1 1498/4885KDM4E 4052/4885 |
| US-20030086933-A1 | Therapeutic systems | NQO2, NQO1, NAPRT | ACHE 4315/4885ALDH1A1 1498/4885KDM4E 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.